SOLICITATION NOTICE
66 -- Multirad 225 Biological X-Ray Irradiator
- Notice Date
- 9/14/2016
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334517
— Irradiation Apparatus Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM
- Archive Date
- 10/5/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- (i) "This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued." (ii) The solicitation number is HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM and the solicitation is being posted as a request for proposal (RFP) to procure: a MultiRad 225 Biological X-Ray Irradiator on behalf of National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering (NIBIB) (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-89-1, August 15, 2016 (iv) This is Small Business set-aside, the associated NAICS Codes: 334517, Irradiation Apparatus Manufacturing and small business size standards is 1000. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on September 20, 2016. Proposals can be emailed to the Contracting Officer, Dorothy Maxwell, Contracting Officer at maxwelld@mail.nih.gov, place Solicitation Number: HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM on the quotation. (v) Background: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institute of Biomedical Imaging and Bioengineering (NIBIB), is dedicated to improving human health through the integration of the physical and biological sciences. The research agenda of the NIBIB will dramatically advance the Nation's health by improving the detection, management, understanding, and ultimately, the prevention of disease. NIBIB's mission is not limited to a single disease, group of illnesses, or population; rather it spans the entire spectrum. We work with doctors from every field of medicine and bring together teams of scientists and engineers from many different backgrounds to develop innovative approaches to health care. The Laboratory of Molecular Imaging and Nanomedicine (LOMIN), LOMIN develops novel methods for incorporating radionuclides into molecules to study biologically important processes for non-invasive PET imaging. The research efforts are driven by a desire to better understand human biology and disease and to generate tools that have clinical imolications. Probes are designed with applications to many important biological processes. Therapeutic efficacy is a key question that needs to be answered for every drug or drug candidate. Molecular imaging is able to provide information to evaluate pharmacological effects. Solid tumors are often characterized by having high glucose utilization, tumor cell proliferation, hypoxia with sustained angiogenesis and evasion of apoptosis. The influence of compounds targeting these characteristics of cancer biology can be selectively visualized by molecular imaging techniques, especially by PET imaging. Examples include FDG PET to image glucose transport and metabolism, and FLT PET to evaluate the proliferating status. The novel PET probes will be applied to target particular pathways such as apoptosis and hypoxia or molecular targets to access specific drugs. LOMIN develops novel nanomaterials for biomedical application, including in vitro high specific and high sensitive diagnostics, in vivo imaging, drug delivery and therapy. Especially, the lab has a Section focusing on Theranostic Nanomedicine, which is the medical application of nanobiotechnology and refers to highly specific medical intervention at the nanoscale for diagnosing, curing or preventing diseases. Theranostic Nanomedicine involves the creation and application of nanobiomaterials and devices at the molecular level for personalized diagnosis, imaging and therapy. Using a multidisciplinary approach, the lab builds new systems for various nanobiomedical applications ranging from the medical use of nanoplatform-based diagnostic agents, to therapeutic agents, and even possible future applications of theranostics (diagnosis + therapy). By integrating state-of-the-art molecular imaging and nanomedicine with peptide/protein chemistry, polymer/inorganic chemistry, nanobioconjugation chemistry, cell/molecular biology as well as clinical medicine, we are developing future nanoplatforms which enable i) early detection of diseases, ii) monitoring therapeutic response, and iii) targeted delivery of therapeutic agents. Its improved practical potency highlights its potential as new personalized strategies to help improve patient management and outcomes in the near future. Purpose and Objectives: The Laboratory of Molecular Imaging and Nanomedicine (LOMIN), NIBIB does research to identify disease-specific biomarkers, to develop new molecular imaging probes, to apply newly developed probes in multimodality imaging, and to characterize novel imaging and therapeutic agents, both in vitro and in vivo. The lab requests a biological X-ray irradiator to fulfill the following research: (1) to develop nanoformulation as radiosensitizers; (2) to develop synergistic therapy combining radiation and chemotherapy; (3) to non-invasively monitor tumor response to radiation therapy. General Specifications: 1. A fully shielded, self-contained cabinet X-ray irradiator capable of up to 225 kVp; 2. Integrated dosimeter; 3. Automatic warm-up and tube conditioning; 4. Uniform dosing; 5. Fully integrated, closed loop cooling system; 6. Adjustable shelf for variable SSDs; 7. Upgrade potential to integrate imaging components; 8. Installation and calibration of the system; on-site training; and 9. One year warranty. Procurement: 1. MultiRad 225 Biological X-Ray Irradiator, Quantity: One. Anticipated Period of Performance: 12-Months Upon Award Deliverables: NIH, 35 Convent Drive, Bethesda, Maryland vi. Include on the RFP, Contractor's Name, Contractor's Address, DUNS, TIN or EIN Number, Solicitation Number, Email Address, Contact Number, Discount. vii. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to this acquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html. EVALUATION OF PROPOSALS: The Government will evaluate proposals that are determined technically acceptable in accordance with the Technical Evaluation factors. The Government intends to award a single contract from this solicitation. The Government reserves the right not to award a contract. Evaluation of Proposals: The Government reserves the right to make an award without discussions based solely upon initial proposals. Price (This will be Firm-Fixed Price): An evaluation of the offeror's price proposal will be made to determine if proposed prices are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the technical proposal. Reasonableness determinations will be made by determining if competition exists, by comparing proposed prices with established commercial or GSA price schedules (if applicable), and/or by comparing proposed prices with the Independent Government Cost Estimate (IGCE). EVALUATION FACTORS: 1. The Multirad 225 Biological X-Ray Irradiator shall provide advanced automated dose measurement and control. 2. The Multirad 225 Biological X-Ray Irradiator shall have the potential to be equipped with a high resolution digital imaging detector, which research laboratory may need the imaging moiety to achieve better dose control and tumor therapy. viii. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to this acquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html. The proposal must reference the RFP Number: HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. All proposals shall contain the following : 1. Name of Contracting Organization; 2. Solicitation number; 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. North American Industry Classification System (NAICS) Code; and 7. DUNS, TIN or EIN Number. x. In accordance to FAR clause 52.212-2, Evaluation - Commercial Items xi. In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, offerors must complete annual representations and certifications on- line at https://www.sam.gov/portal/public/SAM/. xii. FAR clause 52.212-4, Contract Terms and Conditions - Commercial Items applies to this acquisition. xiii. FAR clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items applies to this Acquisition. Additional FAR Clauses include: FAR clause 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (JUL2013) (Pub.L. 109-282) (31 U.S.C. 6101 note). FAR clause 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (AUG2011). FAR clause 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury). FAR clause 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (JUL2013) (31 U.S.C. 3332). xiiii. There are no additional contract requirement(s) or terms and conditions (such as contract financing arrangements or warranty requirements) determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. xv. The Defense Priorities and Allocations System (DPAS) and assigned rating does not apply to this acquisition. xvi. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on September 20, 2016. Proposals can be emailed to the Contracting Officer, Dorothy Maxwell at maxwelld@mail.nih.gov, place Solicitation Number: HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM on the quotation. Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted. Offerors' proposals shall not be deemed received by the Government until the proposal is entered into the e-mail address inbox set forth above. Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(EB)-2016-317-DM/listing.html)
- Place of Performance
- Address: 35 Convent Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04271535-W 20160916/160914235312-3c77173377c62503aeeb5444cd8e1c0e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |